tetano
Editor, Senior Moderator
Int J Med Sci
. 2020 Aug 29;17(15):2373-2378.
doi: 10.7150/ijms.47587. eCollection 2020.
CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
Wang Jia Li[SUP] 1 [/SUP], Zhuo Ma Lv[SUP] 1 [/SUP], Fa Jin Lv[SUP] 1 [/SUP], BinJie Fu[SUP] 1 [/SUP], Liang Bo Hu[SUP] 2 [/SUP], Zhi Gang Chu[SUP] 1 [/SUP]
Affiliations
Abstract
Background: In patients with coronavirus disease 2019 (COVID-19) pneumonia, whether new pulmonary lesions will continue to develop after treatment was unknown. This study aimed to determine whether new pulmonary lesions will develop after treatment in patients with COVID-19 pneumonia, and investigate their CT features and outcomes. Methods: This retrospective study included 56 consecutive patients with confirmed COVID-19 pneumonia from January 20 to March 5, 2020. Their initial and follow-up CT images and clinical data were reviewed. The CT manifestations of primary and newly developed pulmonary lesions and their changes after treatment were mainly evaluated. Results: Among the 56 patients (mean age: 48?15 years, 35 men) with COVID-19 pneumonia, 42 (75.0%) patients developed new pulmonary lesions during treatment. All new lesions developed before the nucleic acid test turned negative. Patients with new lesions were more likely to have lymphopenia (P=0.041) or increased C-reactive protein (CRP) levels (P<0.001) than those without new lesions. Of the 42 patients, 30 (71.4%) patients developed new lesions once, and 12 (28.6%) twice or thrice, which usually appeared when primary lesions were progressing (37, 88.1%) and 1-15 days after treatment. The newly developed lesions were usually multiple (38, 90.5%), distributed in the previously involved (39, 92.9%) or uninvolved (27, 64.3%) lobes, and manifested as ground-glass opacities (GGOs) with consolidation (23, 54.8%) or pure GGOs (19, 45.2%). After their occurrence, the new lesions in most patients (32, 76.2%) showed direct absorption, whereas those in some patients (10, 23.8%) progressed before absorption. Conclusion: During treatment, most patients with COVID-19 pneumonia will develop new pulmonary lesions, which usually manifest as multiple GGOs distributed around the primary lesions or in previously uninvolved lobes, and are subsequently absorbed directly.
Keywords: CT; Coronavirus Disease 2019; New lesions; Pneumonia; Primary lesions.
. 2020 Aug 29;17(15):2373-2378.
doi: 10.7150/ijms.47587. eCollection 2020.
CT features and outcomes of newly developed pulmonary lesions in patients with Coronavirus Disease 2019 (COVID-19)
Wang Jia Li[SUP] 1 [/SUP], Zhuo Ma Lv[SUP] 1 [/SUP], Fa Jin Lv[SUP] 1 [/SUP], BinJie Fu[SUP] 1 [/SUP], Liang Bo Hu[SUP] 2 [/SUP], Zhi Gang Chu[SUP] 1 [/SUP]
Affiliations
- PMID: 32922203
- PMCID: PMC7484640
- DOI: 10.7150/ijms.47587
Abstract
Background: In patients with coronavirus disease 2019 (COVID-19) pneumonia, whether new pulmonary lesions will continue to develop after treatment was unknown. This study aimed to determine whether new pulmonary lesions will develop after treatment in patients with COVID-19 pneumonia, and investigate their CT features and outcomes. Methods: This retrospective study included 56 consecutive patients with confirmed COVID-19 pneumonia from January 20 to March 5, 2020. Their initial and follow-up CT images and clinical data were reviewed. The CT manifestations of primary and newly developed pulmonary lesions and their changes after treatment were mainly evaluated. Results: Among the 56 patients (mean age: 48?15 years, 35 men) with COVID-19 pneumonia, 42 (75.0%) patients developed new pulmonary lesions during treatment. All new lesions developed before the nucleic acid test turned negative. Patients with new lesions were more likely to have lymphopenia (P=0.041) or increased C-reactive protein (CRP) levels (P<0.001) than those without new lesions. Of the 42 patients, 30 (71.4%) patients developed new lesions once, and 12 (28.6%) twice or thrice, which usually appeared when primary lesions were progressing (37, 88.1%) and 1-15 days after treatment. The newly developed lesions were usually multiple (38, 90.5%), distributed in the previously involved (39, 92.9%) or uninvolved (27, 64.3%) lobes, and manifested as ground-glass opacities (GGOs) with consolidation (23, 54.8%) or pure GGOs (19, 45.2%). After their occurrence, the new lesions in most patients (32, 76.2%) showed direct absorption, whereas those in some patients (10, 23.8%) progressed before absorption. Conclusion: During treatment, most patients with COVID-19 pneumonia will develop new pulmonary lesions, which usually manifest as multiple GGOs distributed around the primary lesions or in previously uninvolved lobes, and are subsequently absorbed directly.
Keywords: CT; Coronavirus Disease 2019; New lesions; Pneumonia; Primary lesions.